Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 84Gastrointestinal 6Thoracic 3CNS 3Dermatologic 2Breast 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 29Neoplasm Metastasis 4Breast Neoplasms, Male 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 2Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mesothelioma 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

pembrolizumab 36Nivolumab 16Cyclophosphamide 12atezolizumab 8Docetaxel 8Magnetic Resonance Spectroscopy 7Paclitaxel 6Everolimus 6spartalizumab 5fludarabine 5durvalumab 5Specimen Handling 5Ipilimumab 5cabozantinib 4avelumab 4Trastuzumab 4Radiotherapy 4Radiosurgery 4Oxaliplatin 4Leucovorin 4temsirolimus 3pazopanib 3aldesleukin 3Taxes 3Sunitinib 3Psychiatric Rehabilitation 3Interleukin-2 3Immune Checkpoint Inhibitors 3Gemcitabine 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Sorafenib × Breast × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡